Lonza Partners to Enter Probiotic Space

April 19, 2011

1 Min Read
Lonza Partners to Enter Probiotic Space

BASEL, Switzerland & BERLINLonza and ORGANOBALANCE signed a worldwide exclusive license agreement for Lonza to develop, produce and commercialize products containing a probiotic Lactobacillus strain. The patented strain, developed by ORGANOBALANCE, acts against Helicobacter pylori (H. pylori), a common bacterial infection that has been linked to peptic ulcers and gastritis, by binding to and effectively removing H. pylori from the stomach.

This agreement with ORGANOBALANCE creates a basis for Lonza to enter the probiotic marketa market with vast growth potentialwith a unique ingredient," said Roman Quinter, senior vice president and head of the Nutrition Ingredients business for Lonza. Lonza is a global leader in the manufacturing of intermediates and APIs for the pharmaceutical industry through biotechnology and fermentation. Integrating the Lactobacillus anti-H. pylori strain into our nutrition ingredient portfolio provides an opportunity to leverage our strong biotech expertise and knowledge to provide a highly effective product to the nutrition landscape.

Christine Lang, Ph.D., CEO of ORGANOBALANCE, added: As the leader in the development of innovative probiotic strains, we regard this agreement with Lonza as a further recognition of ORGANOBALANCEs strategy, our expertise, and our innovative capacity. We highly appreciate Lonzas dedication to lead our development into great success on the nutrition marketplace."

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like